Demonstrate the optimal management of oligometastatic prostate, bladder, renal cancer
Explain the role of immunotherapy in the management of bladder, prostate and renal cancer
Determine how to incorporate genomic classifiers, multiple parametric MRI, and clinical parameters into selecting optimal patients with prostate cancer for active surveillance or other definitive management approaches
Apply Level 1 evidence on the use of novel treatment paradigms and updated surveillance options for patients with prostate, renal, bladder, or testicular cancer
Apply novel minimally invasive treatments for GU malignancies including prostate, bladder and kidney cancer
Use multiparametric MRI, fusion biopsy and novel markers in men at risk for prostate cancer
This is an accredited, livestreamed course offered by Brigham and Women's Hospital and Dana-Farber Cancer Institue. This course is targeted to Primary Care Physicians, Specialty Physicians, Nurses, Nurse Practitioners, Pharmacists, Physician Assistants, Psychologists.
Select the Take Course button to view additional information on the course registration page.
Contact ceprograms@hms.harvard.edu with questions.
*Register before July 1 to receive the discounted price.
